In a research note, Edison predicted Epidiolex will generate peak sales of $195m in Dravet syndrome, $601m in Lennox-Gastaut and $255 million in TSC, based on a 2018 launch year.

For example, GW Pharmaceuticals, the company behind Epidiolex and the biggest firm developing cannabis-based medicines, develops its extracts from a stock of identical cannabis clones and a common ...

GW Pharmaceuticals is closing in on a US filing for its cannabinoid epilepsy drug, Epidiolex, after trumpeting late-stage study findings. The company specialises in drugs derived from the cannabis ...

Epidiolex sales beat the Zacks Consensus Estimate and our model estimate of $265 million and $255 million, respectively.